Award$480KView procurement thread

SUPPLY of LUTATHERA® (lutetium Lu 177 dotatate) and PLUVICTO™ (lutetium Lu 177 vipivotide tetraxetan)view on SAM.gov

DEPT OF DEFENSE › DEFENSE HEALTH AGENCY

Posted Oct 8, 2026

Bethesda, MD

Sol # 12481254

Awardee: Novartis Pharmaceuticals Corporation

AI Summary

• WRNMMC requires Pluvicto for targeted radioligand therapy of specific prostate cancers.
• Acquisition is a sole-source procurement due to Novartis being the only source.
• Therapy is for Nuclear Medicine Division of the Department of Radiology at WRNMMC.

Description

Clinical Utility: It is used for targeted radioligand therapy for specific types of prostate cancer within the Nuclear Medicine Division of the Department of Radiology at WRNMMC. Novartis Pharmaceuticals Corporation is the sole source for Pluvicto. Therefore, the recommended course of action is to award a contract directly to Novartis. This approach is deemed to be in the government's best interest to ensure the seamless delivery of these critical supplies and maintain continuity of patient care at WRNMMC. The acquisition will be treated as a sole-source procurement.

Award Details

Contract #HT001426FE141

Award DateSep 30, 2026

Amount$480K

AwardeeNovartis Pharmaceuticals Corporation

Awardee LocationEast Hanover, NJ, 07936

Place of Performance

CityBethesda

StateMD

ZIP20889

CountryUNITED STATES

Contracting Office

OfficeDEFENSE HEALTH AGENCY

CityFALLS CHURCH

StateVA

ZIP22042

Related opportunities

Pump subassembly axial piston hydraulicDEPT OF DEFENSE
Sources Sought (LTC) - 33 NIINsDEPT OF DEFENSE
59--HARNESS,ELECTRICALDEPT OF DEFENSE
16--ELECTRIC BRAKE ACTU, IN REPAIR/MODIFICATION OFDEPT OF DEFENSE
61--PRM/AAU/CHI PWA,AI, IN REPAIR/MODIFICATION OFDEPT OF DEFENSE
28--POWER UNIT,GAS TURBDEPT OF DEFENSE